Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Blood pressure hormone may inhibit growth of lung cancer

02.08.2004


A hormone that is important in the control of blood pressure may also inhibit the growth of lung cancer cells, say scientists at Wake Forest University Baptist Medical Center, writing in the new issue of the journal Carcinogenesis.



Patricia E. Gallagher, Ph.D., and E. Ann Tallant, Ph.D., said the hormone, called angiotensin-(1-7), "may represent a novel chemotherapeutic and chemopreventive treatment for lung cancer."

Their studies found that angiotensin-(1-7) significantly slows the growth of three different types of human lung cancer cells in the laboratory. "Our experiments provide the first evidence that angiotensin-(1-7) inhibits the proliferation of human lung cancer cells," they said.


They hypothesized that the hormone serves as a natural regulator of cell growth, both by reducing the rapid proliferation of cells common in cancer and by increasing cancer cell death.

Gallagher and Tallant have been working with angiotensin-(1-7) for years as members of the Hypertension and Vascular Disease Center faculty. The director of the center, Carlos M. Ferrario, M.D., discovered angiotensin-(1-7) in 1988, and found it to be a critical element of the blood pressure control system.

Angiotensin-(1-7) relaxes (dilates) the walls of the blood vessels, causing blood pressure to be lowered while its hormonal counterpart, angiotensin II, constricts blood vessels, causing blood pressure to rise. A major class of blood pressure medications, called ACE inhibitors, work by reducing angiotensin II and increasing angiotensin-(1-7).

Evidence from population studies in Scotland had suggested that people who were taking ACE inhibitors for high blood pressure had a reduced risk both of cancer occurrence and of cancer death. The effect was most pronounced in lung cancer.

"Our results suggest that the reduced cancer risk observed in patients after administration of ACE inhibitors may be due, at least in part, to the elevated levels of angiotensin-(1-7)," Tallant and Gallagher said.

The cells for their research came from lung cancers in a 60-year-old female, a 58-year-old male and a 65-year-old male. None of the other angiotensin hormones tested slowed the growth of these lung cancer cells.

Tallant and Gallagher said their studies may point the way to a more successful treatment for lung cancer, still one of the most deadly forms of cancer, with only 13 percent of patients alive after five years.

They said either the administration of angiotensin-(1-7) directly, or through compounds that elevate the angiotensin circulating through the body, such as ACE inhibitors, may both treat and prevent lung cancer, with reduced side effects.

The work was supported by the National Institutes of Health and by a pilot project grant from the Comprehensive Cancer Center of Wake Forest University.

Robert Conn | EurekAlert!
Further information:
http://www.wfubmc.edu

More articles from Health and Medicine:

nachricht Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

A new dead zone in the Indian Ocean could impact future marine nutrient balance

06.12.2016 | Earth Sciences

Significantly more productivity in USP lasers

06.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>